Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04572269 · ClinicalTrials.gov registry record
Metabolomics of Obstructive Sleep Apnea
A clinical trial, sponsored by University of Pennsylvania.
- Completed
- Registry status
- 388
- Enrollment target
NCT04572269: Completed study, sponsored by University of Pennsylvania.
NCT04572269 is a clinical trial that has completed, run by University of Pennsylvania. The registered enrollment target is 388 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04572269 has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- 388 participants
- Enrollment target
Study Summary
This is an R01 funded project that focuses on the utility of metabolomics as a biomarker for OSA. Aims 1 and 3 leverages banked samples previously collected from subjects with and without OSA at the University of Pennsylvania and University of Iceland. Aim 2 is a prospective study that will collect serum samples from OSA subjects at the University of Pennsylvania and the University of Iceland.
Interventions
- OTHER No Intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 388 participants |
| Start Date | 2020-09-29 |
| Est. Completion | 2025-09-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04572269
The ClinicalTrials.gov registry entry for NCT04572269 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 388 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which No Intervention is the first listed.
NCT04572269 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04572269 about?
NCT04572269 is a clinical study titled "Metabolomics of Obstructive Sleep Apnea". This is an R01 funded project that focuses on the utility of metabolomics as a biomarker for OSA. Aims 1 and 3 leverages banked samples previously collected from subjects with and without OSA at the University of Pennsylvania and University of Iceland. Aim 2 is a prospective study that will collect ...
What is the current status of trial NCT04572269?
This trial is currently completed. The enrollment target is 388 participants. The study started on 2020-09-29. Estimated completion is 2025-09-12.
What interventions are being tested in trial NCT04572269?
The interventions under investigation include: No Intervention (OTHER).
Who is sponsoring clinical trial NCT04572269?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.